But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP ...

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.

Pharma major Lupin Ltd on Thursday said it has  received approval from the US health regulator for its generic version of ...

Alzforum webpages for each DIAN-TU-eligible variant now state “DIAN-TU eligibility: Yes” near the top of the page and an ...

Q1 2023 Earnings Call Transcript April 15, 2025 Spruce Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Real-world data supports tolvaptan use to slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).

An estimated 1 in 3,000 individuals may carry a genetic variant tied to pneumothorax and RCC—approximately 100 times more ...

Police are investigating an incident of 'large disorder' on a city street. The trouble reportedly flared on Fenton's Smithpool Road on Friday. In the aftermath families in the area were warned to ...

Stereotypic movement disorder is a condition in which a person engages in repetitive, often rhythmic, but purposeless movements. In some cases, the movements may result in self-injury. For this ...